A carregar...
Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
INTRODUCTION: Patients with liver cirrhosis are often diagnosed late and once complications are present, the 2-year survival is 50%. Increasing evidence supports systemic inflammation and metabolic dysfunction in the hepatic stellate cell as key drivers of progression of cirrhosis. However, there is...
Na minha lista:
| Publicado no: | BMJ Open |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7045122/ https://ncbi.nlm.nih.gov/pubmed/31980514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-035284 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|